Literature DB >> 35239079

Clinicopathological features and prognosis of gastric tube cancer after esophagectomy for esophageal cancer: a nationwide study in Japan.

Mitsuhiko Ota1, Masaru Morita1, Masahiko Ikebe1, Yuichiro Nakashima1, Manabu Yamamoto1, Hisahiro Matsubara2,3, Yoshihiro Kakeji4,3, Yuichiro Doki5,3, Yasushi Toh6,7.   

Abstract

BACKGROUND: Survivors of esophageal cancer post-esophagectomy may sometimes develop gastric tube cancer (GTC). However, its clinical characteristics have not been elucidated. We conducted a retrospective nationwide survey of GTCs to clarify them.
METHODS: A questionnaire on GTCs was sent by e-mail and mail to 116 institutions certified by the Japan Esophageal Society. A total of 608 GTC cases diagnosed and treated between 2001 and 2015 were registered from 62 institutions.
RESULTS: The median age at diagnosis was 71 years, with 88.9% being diagnosed with stage I. Sixty percent of GTC cases were in the anal third of the gastric tube and 79.7% were differentiated adenocarcinomas. The median interval between esophagectomy and GTC diagnosis was 6 years, with approximately 25% of patients being diagnosed more than 10 years later. The 5-year overall survivals (5-OSs) after endoscopic and surgical treatments for GTC were 75.9% and 52.7%, respectively. Patients whose GTC was diagnosed without symptoms or by regular follow-up examination showed better 5-OSs compared to others (69.7% vs. 41.2%, p < 0.0001; and 71.4% vs. 41.8%, p < 0.0001, respectively). The prognosis of GTC cases diagnosed within 2 years of the preceding upper gastrointestinal endoscopy (UGI) was better than that in cases diagnosed longer than 2 years (5-OS: 73.4% vs. 48.8%, p < 0.05).
CONCLUSION: This nationwide survey revealed the clinicopathological features of GTCs for the first time. Early detection is important in improving the prognosis of GTC, and it is recommended that UGI endoscopy be continued every 2 years for 10 or more years after esophagectomy.
© 2022. The Author(s) under exclusive licence to The Japan Esophageal Society.

Entities:  

Keywords:  Endoscopy; Esophagectomy; Follow-up; Gastric tube cancer

Mesh:

Year:  2022        PMID: 35239079     DOI: 10.1007/s10388-022-00915-8

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  4 in total

1.  Combined 24-hour intraluminal pH and bile monitoring of the denervated whole stomach as an esophageal substitute.

Authors:  R Romagnoli; P Bechi; M Salizzoni; J M Collard
Journal:  Hepatogastroenterology       Date:  1999 Jan-Feb

2.  Gastric tube cancer after esophagectomy for cancer: a systematic review.

Authors:  Damiano Gentile; Pietro Riva; Anna Da Roit; Silvia Basato; Salvatore Marano; Carlo Castoro
Journal:  Dis Esophagus       Date:  2019-08-01       Impact factor: 3.429

3.  Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in Japan.

Authors:  Tomonori Nakanoko; Masaru Morita; Yuichiro Nakashima; Mitsuhiko Ota; Masahiko Ikebe; Manabu Yamamoto; Eisuke Booka; Hiroya Takeuchi; Yuko Kitagawa; Hisahiro Matsubara; Yuichiro Doki; Yasushi Toh
Journal:  Esophagus       Date:  2021-08-12       Impact factor: 4.230

4.  Comprehensive Analysis of Multiple Primary Cancers in Patients With Esophageal Squamous Cell Carcinoma Undergoing Esophagectomy.

Authors:  Naoya Yoshida; Kojiro Eto; Junji Kurashige; Daisuke Izumi; Hiroshi Sawayama; Tomo Horinouchi; Masaaki Iwatsuki; Yoshifumi Baba; Yuji Miyamoto; Hideo Baba
Journal:  Ann Surg       Date:  2020-09-15       Impact factor: 13.787

  4 in total
  1 in total

1.  Is Prophylactic Cervical Drainage Effective in Patients Undergoing McKeown Esophagectomy Reconstructed Through the Retrosternal Route with Two-Field Lymphadenectomy?

Authors:  Daisuke Fujiwara; Masayuki Watanabe; Yasukazu Kanie; Suguru Maruyama; Kei Sakamoto; Akihiko Okamura; Jun Kanamori; Yu Imamura; Shinji Mine
Journal:  World J Surg       Date:  2022-04-20       Impact factor: 3.282

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.